Pharmacogenomics of cetuximab in metastatic colorectal carcinoma
- Autori: Silvestris, N.; Vincenzi, B.; Brunetti, A.; Loupakis, F.; Dell'Aquila, E.; Russo, A.; Scartozzi, M.; Giampieri, R.; Cascinu, S.; Lorusso, V.; Tonini, G.; Falcone, A.; Santini, D.
- Anno di pubblicazione: 2014
- Tipologia: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/295558
Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.